is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). It is used in metastatic colorectal cancer , either with irinotecan in patients refractory to irinotecan-based chemotherapy, or as monotherapy. Cetuximab with radiotherapy is also approved for the ttt of locally advanced squamous cell cancer of the head and neck.
Dosage:250m ./m2/week.
Vial
3026 EGP
is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). It is used in metastatic colorectal cancer , either with irinotecan in patients refractory to irinotecan-based chemotherapy, or as monotherapy. Cetuximab with radiotherapy is also approved for the ttt of locally advanced squamous cell cancer of the head and neck.
Dosage:250m ./m2/week.
Note: All the provided information about this drug does not substitute for consulting a doctor.